INTRODUCTION
Extraordinary excitement over progress in the ability of genomic medicine to connect specific genotypes to disease predisposition has been tempered by the host of challenges in translating such correlations to specific treatments. There is consensus in the field that modeling ''diseases in a dish'' is one of the most promising approaches to address this crucial problem (Vogel, 2010) . Human induced pluripotent stem cell (hiPSC) technology, which enables the epigenetic reprogramming of human somatic cells into an embryonic stem cell-like state followed by differentiation into any cell type of the body, is being developed as a key component of such in vitro disease modeling (Dimos et al., 2008; Park et al., 2008; Soldner et al., 2009; Takahashi et al., 2007; Yu et al., 2007) . In principle, patient-specific iPSCs that carry all disease-relevant genetic alterations could provide researchers with a unique opportunity to study the cellular and molecular mechanisms of monogenic and complex diseases in relevant cell types in vitro with the potential to identify alternative treatments (Daley and Scadden, 2008; Saha and Jaenisch, 2009) .
However, so far, only a few such studies have identified disease-related phenotypes, mostly in rare, early age onset or metabolic diseases (Brennand et al., 2011; Ebert et al., 2009; Itzhaki et al., 2011; Lee et al., 2009; Marchetto et al., 2010; Rashid et al., 2010) . Due to the robust and rapid manifestation of these disorders, in vitro models are more likely to display clear differences when compared to healthy donor controls. In contrast, late age onset disorders, such as Parkinson's and Alzheimer's diseases, with long latency and slow progression of cellular and pathological changes in vivo are expected to show only subtle phenotypes in vitro. To distinguish these subtle but disease-relevant phenotypical changes from unpredictable background-related variations could prove difficult due to the lack of genetically matched controls. Commonly used control cells from healthy donors represent an approximate solution at best because individual hESC and hiPSC lines display highly variable biological characteristics such as the propensity to differentiate into specific functional cells (Bock et al., 2011; Boulting et al., 2011; Soldner et al., 2009) . The basis for these profound differences is manifold and includes: (1) differences in genetic background; (2) the process of cell derivation (Lengner et al., 2010); and (3) in the case of hiPSCs, variegation effects and residual transgene expression of the viral vectors used to induce reprogramming and genetic alterations introduced during the reprogramming process (Gore et al., 2011; Hussein et al., 2011) . Variable genetic background presents a particularly significant impediment to in vitro disease modeling approaches because it is not possible to control for effects from genetic modifier loci. Even mutations that cause the most prevalent monogenic diseases, including sickle cell anemia, cystic fibrosis, and dominant forms of familial Parkinson's disease (PD), are susceptible to significant epistatic effects of genetic background that result in incomplete penetrance and variable age of onset and disease progression (Lees et al., 2009; Summers, 1996) .
Therefore, for the disease in a dish approach to be successful, it is essential to set up experimental systems in which the disease-causing genetic lesion of interest is the sole modified variable. However, the unresolved problem of genetically manipulating pluripotent human cells has prevented the creation of such genetically defined human model systems. Recently, we and others used engineered zinc finger nucleases (ZFNs) to drive efficient targeted integration of selectable markers into hESCs and hiPSCs Zou et al., 2009 ). Employing this technology (referred to as ''genome editing''), we present here a generally applicable solution to this key problem by demonstrating the generation of a panel of isogenic disease and control cell lines from hESCs and hiPSCs that differ exclusively at well-validated susceptibility variants for PD by genetically modifying single base pairs in the a-synuclein gene.
PD, the second most common late age onset neurodegenerative disorder, is characterized primarily by major loss of nigrostriatal dopaminergic neurons and the presence of proteinacious inclusion bodies (Lewy bodies) in affected cells. The discovery of mutations linked to rare forms of familial PD, such as dominant mutations in a-synuclein (A53T, E46K, A30P), the major component of Lewy bodies, has provided vital clues in understanding the molecular pathogenesis not only of the rare familial, but also of the more prevalent sporadic forms of the disease (Lees et al., 2009; Schulz, 2008) . However, cellular and transgenic animal models expressing such mutants only partially recapitulate PD pathology (Dawson et al., 2010) . In order to develop a genetically defined human in vitro model of PD, we sought to generate a panel of control and diseaserelated cell lines by either deriving hiPSCs from a patient carrying the A53T (G209) a-synuclein mutation followed by the correction of this mutation or, alternatively, by generating either the A53T (G209A) or E46K (G188A) mutation in the genome of wild-type hESCs.
RESULTS
Insertion of Disease-Causing A53T (G209A) a-Synuclein Mutation into hESCs Genome editing with engineered ZFNs relies on a double-strand break (DSB) introduced by the nucleases. The ability to precisely target DSB to an investigator-specified site is critical because point mutations are transferred with maximal efficiency from episomal donors into the position of the DSB itself (Elliott et al., 1998; Goldberg et al., 2010) . We engineered a panel of ZFNs that introduces a DSB precisely at nucleotide base 209 (site of A53T mutation) in exon 3 of the a-synuclein gene (Figures 1A  and 1B and Table S1 and Table S2 available online) . Screening of the ZFNs in transformed human cells demonstrated editing of up to 18% of a-synuclein alleles precisely at the intended site ( Figure 1A) .
Guided by our previous results on highly efficient targeted integration of genes in hESCs and hiPSCs , we initially considered a drug selection-based strategy to introduce the PD-causing A53T (G209A) mutation into the endogenous a-synuclein locus in hESCs. However, for many disease-related mutations that are located within protein-coding exons, including a-synuclein A53T (G209A), the same approach cannot be used because insertion of the selection marker would disrupt the expression of the targeted gene. We therefore devised an alternative strategy based on the insertion of a loxP site flanked puromycin resistance gene in the adjacent intron 23 bases downstream of the A53T a-synuclein mutation and the DSB ( Figure 1B ). For this gene editing strategy, a correct targeting event followed by Cre-recombinase-mediated excision of the selection cassette is expected to result in a single base pair change that creates the A53T (G209A) mutation in exon 3 of a-synuclein, with a remaining single loxP site in the following intron ( Figure 1B) .
The targeting donor construct (Syn-A53T-loxP-pGK-puroloxP) comprising $600 bp homology on each side of the ZFNtargeted site carrying the A53T (G209A) mutation ( Figure 1B) , together with four distinct ZFN pairs (Table 1, Figure 1A, Table  S1, and Table S2 ), were electroporated into two different hESC lines (BGO1 and WIBR3). Southern blot analysis of individual single-cell-derived puromycin-resistant clones using probes 5 0 and 3 0 external to the donor homology region demonstrated the disruption of the genomic locus and integration of the targeting donor vector with a frequency of at least 25% ( Figure 1C , Figure S1A, and Table 1 ). Further analysis using an internal probe against the 3 0 targeting arm of the donor vector ( Figure S1B ) and against the ampicillin resistance gene ( Figure S1C ) revealed integrations of additional donor-derived vector sequences into the target locus, presumably via a hybrid homology directed repair (HDR)-end-joining-based process such as described previously (Richardson and Jasin, 2000) .
Three out of 336 puromycin-resistant clones showed the correct modification of the targeted genomic locus by Southern blot ( Figure 1C , Figure S1 , and Table 1), which was further confirmed by sequencing after Cre-mediated excision of the selection cassette ( Figure 1D ). Two out of the three clones carried a small deletion in the second allele as a result of ZFN-mediated gene disruption. The correctly targeted clone with a nondisrupted wild-type allele (WIBR3-SNCA A53T/WT -1A/-1C) displayed a normal karyotype ( Figure S1D ) and maintained a pluripotent state, as indicated by the uniform expression of pluripotencyspecific marker proteins ( Figure 1E ) and the ability to form teratomas comprising cell types originating from all three developmental germ layers ( Figure 1F ). The stable integration of the transiently transfected ZFN or Cre-recombinase-expressing plasmids was excluded by Southern blot analysis ( Figure S3 ). Furthermore, using an embryoid body (EB)-based protocol to induce neural differentiation, we were able to efficiently derive dopaminergic thyrosine hydroxylase (TH)-expressing neurons from the targeted hESC line ( Figure 1G ). To verify that the loxP site remaining after Cre-mediated excision of the selection cassette does not interfere with the splicing or gene expression of a-synuclein, we differentiated the parental and targeted hESC lines into neurons in order to induce expression of a-synuclein. Mutation analysis RT-PCR (Polymeropoulos et al., 1997) confirmed that the levels and ratio of expression of the wild-type and the A53T-mutated transcript in the targeted cell line were similar to those observed in neurons derived from A53T patient-specific hiPSCs (WIBR-iPS-SNCA A53T(1lox) ) ( Figure 1H ). In order to increase the targeting efficiency by reducing nontargeted integrations of the donor vector, as well as integration of donor vector sequences that are outside of the homology arms at the site of ZFN cleavage, we employed a positive-negative selection strategy (Capecchi, 1989) by incorporating the herpes simplex virus thymidine kinase (HSV-TK) and diphtheria toxin A-chain (DT-A) into the vector backbone ( Figure 1B ). Using this strategy, 9 out of 41 puromycin-and ganciclovir-resistant colonies resulted in a correctly targeted allele ( Figure 1I and Table 1 ). Four of these clones had no disruption of the second wild-type allele, and 1 out of the 41 clones resulted in correct targeting and insertion of the A53T (G209A) mutation into both alleles (WIBR3-SNCA A53T/A53T ). The targeted clones initially identified by Southern blot analysis were confirmed by sequencing of the genomic locus (data not shown). None of the clones integrated the transiently transfected ZFNs (Figure S3 ). This single step biallelic modification of a disease-relevant locus represents a unique tool to study the role of mutant a-synuclein in the absence of the wild-type protein. Individuals that are homozygous for this mutation have not been described, and the study of homozygous mutant cells may provide new insights into the pathogenesis of PD.
Insertion of the A53T (G209A) Point Mutation into the a-Synuclein Gene without Drug Selection
The experiments described thus far, though successful in transferring a desired point mutation to the native locus, required the integration of a selectable marker into a neighboring intron. Dependent on the location of the desired editing events relative to intron/exon junction, such strategy may not be applicable to all genes; in addition, whereas the selectable marker can be excised using Cre-recombinase, the remaining loxP site represents an additional nonrequired genetic alteration with possible unpredictable effects. We therefore turned to an approach aimed at generating genetically pristine hESCs that contain no exogenous sequences other than the edited base (Urnov et al., 2005) for introducing the disease-causing point mutation (Figure 2A) . Given the high gene editing activity of the ZFNs (Figure 1A , Figure S1A , and Table 1 ), we constructed a donor vector lacking a selection cassette, consisting only of $1 kb homology flanking the ZFN cleavage site carrying the A53T (G209A) point mutation in order to insert the mutation in the endogenous a-synuclein locus in hESCs ( Figure 2A ). The hESC line BGO1 was electroporated with the donor construct together with ZFNs and an eGFP-expressing plasmid, which allows transfected cells to be enriched by fluorescence-activated cell sorting (FACS). Singlecell-derived colonies derived from this enriched pool were screened by Southern blot analysis using an A53T (G209A) allele-specific Tsp45I restriction digest. Three out of 240 BGO1 clones showed the A53T (G209A) allele-specific restriction pattern, indicative of an accurate genetic alteration event resulting in a A53T (G209A) mutation at the endogenous genomic locus ( Figure 2B ). Further analysis by PCR genotyping ( Figure 2C ) and sequencing of the genomic locus ( Figure 2D ) confirmed one correctly targeted clone (Table 1) (B) Schematic overview depicting the genomic a-synuclein locus (SNCA) and the targeting strategy showing exons (blue boxes), restriction sites, and location of external and internal Southern blot probes (red bars). Enlarged sequence indicates ZFN-induced cut site at base 209 in exon 3 of a-synuclein (red base pair) and insertion site of loxP-site-flanked pGK-puro selection cassette (red box). Shown below is a schematic of the donor plasmid design for either positive selection (Syn-A53T-loxP-pGK-puro-loxP) or positive-negative selection (Syn-A53T-loxP-pGK-puro-loxP-HSV-TK-DT-A) and targeted genomic locus before and after Cre-excision of the selection cassette. Donor plasmids comprise $600 bp homology on each side of the ZFN cut. pGK-promoter, phosphoglycerol kinase promoter; puro, puromycin resistance gene; pGKpolyA, polyadenylation sequence; HSV-TK, herpes simplex virus thymide kinase; pGK-DT-A-pA, diphtheria toxin A-chain. ). The targeted cell line maintained a pluripotent state, as indicated by the uniform expression of pluripotency-specific markers ( Figure 2E ) and the ability to form teratomas ( Figure 2F ) and differentiate into dopaminergic neurons in vitro ( Figure 2G ). The stable integration of the ZFNs and GFP expression plasmids was excluded by Southern blot analysis ( Figure S3 ).
Insertion of the PD-Causing E46K (G188A) Point Mutation into a-Synuclein in hESCs Using SingleStranded Oligodeoxynucleotides Recent studies suggest that short single-stranded oligodeoxynucleotides (ssODNs) instead of double-stranded donor plasmids can be used as an alternative DSB repair template for ZFN-driven genome editing Radecke et al., 2006 Radecke et al., , 2010 . As it has been shown that point mutations can be transferred distant from the ZFN-induced DSB (Elliott et al., 1998; Goldberg et al., 2010) , we wanted to test the possibility of introducing a second PD-causing mutation (E46K/G188A) into exon 3 of a-synuclein (Zarranz et al., 2004 ) and therefore designed a 114 bp ssODN carrying the disease-relevant G188A base pair change, located 21 bases upstream of the A53T (G209A) mutation ( Figure 3A) . The hESC lines BGO1 and WIBR3 were electroporated with ZFNs and an eGFP-expressing plasmid together with the ssODNs instead of a double-stranded donor vector ( Figure 3A) . Individual single-cell-derived clones from FACS-sorted eGFP-expressing cells were screened by PCR followed by the mutation-specific StyI restriction digest. Four out of 480 WIBR3 clones and one out of 240 BGO1 clones showed the E46K (G188A) allele-specific loss of the StyI restriction site as verified by PCR genotyping (Zarranz et al., 2004) and Southern blot analysis ( Figures 3B and 3C) , indicative of the accurate genetic alteration of the endogenous a-synuclein genomic locus. Further analysis by sequencing of the genomic locus confirmed the correct insertion of the E46K (G188A) mutation without any additional alteration of the wildtype or mutated allele adjacent to the ZFN cleavage site ( Figures  3D and 3E ). The targeted cell lines maintained a pluripotent state, as indicated by the uniform expression of pluripotency-specific marker proteins (Figures 3F and 3G ). The efficiency of correctly genome edited clones using ssODNs as template was comparable to that of using double-stranded donor plasmids (Table 1) . Figure S1 ). b Insertion of A53T (G209A) mutation, as analyzed by Southern blot after TSP45I digest, genomic PCR mutation analysis, and sequencing. c Loss-of-A53T (G209A) mutation, as analyzed by Southern blot after TSP45I digest, genomic PCR mutation analysis, and sequencing. Genetic Repair of the A53T (G209A) a-Synuclein Mutation in PD Patient-Derived hiPSCs Fibroblasts obtained from a patient carrying the A53T (G209A) a-synuclein mutation were reprogrammed using previously described doxycycline-inducible and Cre-recombinase-excisable lentiviral vectors (Hockemeyer et al., 2008; Soldner et al., 2009 ). The resulting hiPSCs before (WIBR-iPS-SNCA A53T(2lox) ) ( Figure 4 ) and after Cre-mediated excision of the reprogramming factors (WIBR-iPS-SNCA A53T(1lox) ) ( Figure S2 ) displayed all basic
properties of pluripotent cells, as indicated by the uniform expression of the pluripotency marker proteins ( Figure 4A and Figure S2B ), the ability to form teratomas ( Figure S2C ), and a normal karyotype ( Figure 4B ). Sequencing of the genomic a-synuclein locus confirmed the A53T (G209A) mutation in the patient-derived hiPSCs ( Figure 4D) . Furthermore, the cells were shown to differentiate into TH-expressing dopaminergic neurons ( Figure 4E ). In order to genetically repair the A53T (G209) mutation in the PD patient-derived hiPSCs, we employed a selection-free targeting strategy, as described above for hESCs, with the only difference of using a wild-type sequence-containing donor vector (Figure 2A ). Six out of 240 WIBR-iPS-SNCA A53T clones demonstrated the loss of the A53T-specific Tsp45I restriction site by Southern blot screening, which is either the result of a ZFN-induced DSB followed by nonhomologous error-prone end-joining or HDR-based correction of the allele ( Figure 5A ). Further analysis by PCR genotyping ( Figure 5B ) and sequencing of the genomic locus ( Figure 5C ) confirmed one correctly repaired patient-derived hiPSC line (WIBR-iPS-SNCA A53T-Corr ; Figure S2D ), which subsequently displayed a normal karyotype ( Figure 5E ), maintained a pluripotent state as indicated by the uniform expression of the pluripotency markers ( Figure 5F ), and displayed the ability to form teratomas ( Figure 5G ). Stable integration of ZFNs, Cre-recombinase, and GFP expression plasmids was excluded by Southern blot analysis ( Figure S3 ). The genetic repair of the A53T mutation in the patient-derived hiPSCs did not compromise the ability to differentiate into TH-expressing dopaminergic neurons ( Figure 5H ). To further validate accurate editing of the a-synuclein locus in the repaired patient-derived hiPSC line (WIBR-iPS-SNCA A53T-Corr ), we performed mutation analysis RT-PCR of a-synuclein after neuronal differentiation, confirming the loss of expression of the mutated A53T (G209A) transcript ( Figure 5D ).
Genome-wide Analysis of Engineered ESCs and iPSCs
A potential limitation of ZFN-mediated genome editing is the induction of DNA strand breaks at sequences other than the intended target site. To examine off-target modifications in the edited cell lines, we initially determined the DNA binding specificity for each ZFN employed in this study by SELEX analysis, as described previously Perez et al., 2008) (Table S3 ). This allows for the identification of the most probable off-target cleavage sites genome-wide (Table S4) . A Surveyor endonuclease (Cel-1) assay was subsequently performed to reveal any potential nonhomologous end-joining (NHEJ)-mediated indels for a large panel of putative off-target sites in several of our edited cell lines (Table 1 and Figure S4 ). Although this analysis has revealed rare bona fide off-target modification by ZFNs in other studies Perez et al., 2008) , we saw no evidence of off-target genome disruption at any of the examined loci (Table1 and Figure S4 ).
It is well established that prolonged culture of hESCs can lead to adaption such as increased growth rate, reduced apoptosis, and the acquisition of chromosomal abnormalities such as copy number variations (CNVs) (Laurent et al., 2011; Nä rvä et al., 2010) . More recently, it has been proposed that the reprogramming process itself compromises genomic integrity and leads to the accumulating of CNVs and somatic mutations (Gore et al., 2011; Hussein et al., 2011) . Although all of our tested cell lines showed a normal karyotype after genome editing as determined by conventional karyotyping, the low resolution of this technology excludes the detection of smaller CNVs, which are considered a major source for human genome variability and particularly important in the context of genome editing. Such genetic modifications involve the induction of DNA double-strand breaks and clonal events, which are thought to increase the chance for additional genomic alterations. We therefore performed high-resolution genome-wide CNV analysis using an Affymetrix SNP 6.0 array, as described previously (Hussein et al., 2011; Nä rvä et al., 2010) , on three pairs of isogenic parental and genetically modified cell lines. We identified, on average, 77 CNVs with an average size of 158 kb per cell line (Table S5) . For human ES cell lines, this is slightly higher than described previously and may be due to technical variability such as low sample or higher passage number of the cell lines used in this study (between passage P25 and P60 for hESCs and P22 and P40 for hiPSCs). Sixty-three percent of the identified CNVs (number and total genomic area) overlapped between isogenic pairs using pairwise comparison before and after ZFNs-mediated genome modification ( Figures S5A-S5E ). In contrast, we observed only 35% overlap of CNVs between genetically unrelated samples ( Figures S5A-S5E ). This degree of overlap is comparable to previously published hESC data comparing identical cell lines at different passage numbers ( Figures S5D and S5E ) (Nä rvä et al., 2010) . Furthermore, comparing average number and total genome area of CNVs before and after ZFN-mediated gene targeting did not reveal any additional change other than that observed during regular hESCs in culture ( Figure S5F ). Consistent with previous reports (Nä rvä et al., 2010) , our analysis confirms that hESCs and hiPSCs contain a higher number of CNVs than the normal human genome independent of the genome editing procedure-probably acquired during hESC derivation, the reprogramming process, and prolonged cell culture. Moreover, we conclude that the Cre-recombinase-mediated excision of the reprogramming factors and ZFN-mediated genome editing did not substantially increase the level of genomic alterations. To further validate that the genome editing approach did not induce major genetic or epigenetic alterations that would result in aberrant gene expression profiles, we performed whole-genome expression analysis of undifferentiated pairs of parental and genetically modified cell lines. Despite very similar gene expression of all pluripotent cell lines, hierarchical cluster analysis showed that the influence of genetic background on gene expression is more significant than the genome editing because gene expression patterns of pairs of parental and genome-edited cell lines are more closely correlated than genetically independent cell lines ( Figure S5G ). (G) Immunofluorescence staining of neuronal cultures derived from BGO1-SNCA A53T/WT cells 10 days after induction of differentiation for neuron-specific class III b-tubulin (TUJ1; green) and the dopaminergic neuron-specific marker tyrosine hydroxylase (TH; red). (G188A) mutation. Genomic DNA was digested using an E46K (G188A) allele-specific StyI restriction digest (E46K mutation disrupts wild-type allele specific StyI restriction site). Expected fragment sizes: wild-type allele, 0.46 kb; E46K mutated allele, 2.96 kb. (D) Sequencing of genomic a-synuclein locus in targeted hESC clone WIBR3-SNCA E46K displaying either wild-type allele (G188 in 10 out of 16 sequences) or targeted mutant E46K allele (A188 in 6 out of 16 sequences). (E) Sequencing of genomic a-synuclein locus in targeted hESC clone BGO1-SNCA E46K displaying either wild-type allele (G188 in 7 out of 16 sequences) or targeted mutant E46K allele (A188 in 9 out of 16 sequences). (F) Immunofluorescence staining of WIBR3-SNCA E46K for the pluripotency markers OCT4, NANOG, SOX2, Tra-1-60, Tra-1-81, and SSEA4.
(G) Immunofluorescence staining of BGO1-SNCA E46K for the pluripotency markers OCT4, NANOG, SOX2, Tra-1-60, Tra-1-81, and SSEA4.
DISCUSSION
Although transgenic animal models of disease and studying human cultured cells in a Petri dish are core technologies driving basic biomedical research, there are many instances in which these approaches only partially recapitulate the molecular and cellular changes observed in the patient. The ability to generate an unlimited supply of patient-derived, disease-relevant cell types using hiPSC technology has the potential to transform biomedical research of human disease. However, numerous challenges on the path to well-defined experimental in vitro systems must be resolved before realizing the full promise of this technology. One of the crucial limitations has been the inability to perform experiments under genetically defined conditions. Here, we present an elegant solution to this problem by combining the advantages of ZFN-mediated gene editing such as the ability to engineer ZFNs to target any locus in the genome (Urnov et al., 2010) and easy donor design, requiring only very short targeting homologies, with hESC and hiPSC technology. The recent demonstration of efficient gene editing in human pluripotent cell lines using transcription activator-like effector (TALE) nucleases as an alternative strategy to induce site-specific genomic DSBs will further expand the versatility of this approach (Hockemeyer et al., 2011) . Table 2 compares the strengths and the weaknesses of the four strategies described in this study. Although a gene-targeting vector using positive-negative selection represents the most efficient genome editing strategy, this approach requires the deletion of the selection cassette and therefore necessitates a second single-cell cloning step, adding time to generate the final targeted cell line. Another unavoidable consequence of the selection-based strategy is that it leaves a genetic footprint, such as a loxP site, close to the targeted genetic alteration. In contrast, the selection-free strategy, though less efficient, leaves no genetic footprint and involves only one cell cloning step and thus shortens the time required to generate the targeted cell line. The simplicity of synthesizing ssODNbased donors combined with the ability to transfer genomic alterations adjacent to the ZFN induced DSB greatly increases the versatility and applicability of the no-selection-based approach and may represent the most advantageous option for genome editing.
Here, we generated a panel of isogenic control and disease cell lines on several defined genetic backgrounds by either engineering the PD-related A53T or E46K mutation into hESCs or, inversely, repairing the mutation in PD-patient-derived hiPSCs by exclusively changing a single base pair without the need to alter the genome in any other way. Considering the broad influence of genetic background and the profound biological differences between individual hESCs and hiPSCs, such as the propensity to differentiate toward specific cell lineages (Bock et al., 2011; Boulting et al., 2011) , this experimental system may overcome some of the shortcomings of conventional hiPSC approaches in identifying disease-related phenotypes. Robust disease-relevant in vitro phenotypes are fundamentally important to identify new drug targets or allow large-scale screening of genetic and small-molecule disease modifiers. The availability of genetically defined pairs of disease and control cell lines becomes even more significant in the context of unbiased genome-wide analysis in order to distinguish between genetic background noise and disease relevant effects, considering that the expression of $5% of genes is thought to be linked to genetic variation (Montgomery et al., 2010; Pickrell et al., 2010) .
Though biomedical research is likely to benefit substantially from in vitro disease modeling, the ultimate promise of iPSC technology, albeit at a very early stage of development, is the concept of cell replacement therapy in degenerative diseases using autologous cells (Daley and Scadden, 2008) . Proof-ofprinciple experiments in the mouse (Hanna et al., 2007) have established the feasibility of treating monogenic diseases using the combined approach of derivation of disease-specific iPSCs followed by in vitro repair of the underlying genetic alteration and subsequent transplantation of corrected iPSC-derived cells. Similar approaches with human cells are currently hindered by the problem of efficient gene targeting required for repair of disease-causing genomic alterations (Daley and Scadden, 2008) . The methods described here for genetically correcting a disease-causing point mutation in patient-derived hiPSCs should be widely applicable and important both for elucidating disease mechanism and for moving toward hiPSC-based cell replacement therapies. (Lengner et al., 2010) and hiPSCs were derived and maintained as described previously and in detail in the Extended Experimental Procedures. The patient biopsied harbors the A53T a-synuclein mutation and has been described previously (Golbe et al., 1996) . All protocols were approved by the relevant Institutional Review Boards (Boston University Medical Campus; Massachusetts Institute of Technology) and Embryonic Stem Cell Research Oversight Committees (Whitehead Institute), and written informed consent was obtained before biopsy. All pluripotent cell lines have been characterized by conventional methods, which are described in detail in the Extended Experimental Procedures.
ZFN Design and ZFN Expression Plasmids
ZFNs against the human a-synuclein locus were designed using an archive of prevalidated two-finger modules, as described (Doyon et al., 2008; Miller et al., 2007; Perez et al., 2008; Urnov et al., 2005) . Complete sequences of target sites of the zinc finger proteins are provided in Table S1 and Table S2 . All ZFNs were linked to wild-type FokI, except pair SNCA-L1/R3, which was linked to an obligate heterodimer form of the Fok1 endonuclease (ELD-KKR) (Doyon et al., 2011; Miller et al., 2007; Perez et al., 2008 ). The ZFNs were tested by transient transfection into K562 cells to test for disruption of the wild-type a-synuclein allele. Disruption efficiency at the target locus was determined by Surveyor (Cel-1) endonuclease-based measurement of nonhomologous end-joining, as described (Miller et al., 2007; Perez et al., 2008) (primers used in Cel-1 analysis: SNCA-Cel1-FW, 5 0 -AAACTAGCTAATCAGCAATT TAAGGC-3; SNCA-Cel1-RW, 5 0 -AGCCCTCATTATTCTTGGCA-3). Analysis of off-target cleavage by ZFNs, which results in NHEJ-mediated indels, was performed essentially as described before (Doyon et al., 2008; Hockemeyer et al., 2009; Perez et al., 2008) and is described in detail in the Extended Experimental Procedures.
ZFN-Mediated Genome Editing of hESCs and hiPSCs
HESCs and hiPSCs were cultured in Rho-associated protein kinase (ROCK) inhibitor (Calbiochem; Y-27632) 24 hr prior to electroporation. Cells were harvested using 0.05% trypsin/EDTA solution (Invitrogen) and were resuspended in phosphate buffered saline (PBS). For drug selection-based gene editing, 1 3 10 7 cells were electroporated with 35 mg of donor plasmids (designed and assembled by F.S.) and 7.5 mg of each ZFN-encoding plasmid (Gene Pulser Xcell System, Bio-Rad: 250 V, 500 mF, 0.4 cm cuvettes). Cells were subsequently plated on DR4 MEF feeder layers in hESC medium supplemented with ROCK inhibitor for the first 24 hr. Ganciclovir (1 3 10 À6 M) and/or puromycin selection (0.5 mg/ml) was started 72 hr after electroporation. For drug selection-free gene editing, 1 3 10 7 cells were electroporated with 30 mg of donor plasmids (designed and assembled by F.S.), 7.5 mg of each ZFN-encoding plasmid, and 10 mg of pEGFP-N1 (Clontech). For gene editing using ssODNs, 1 3 10 7 cells were electroporated with 7.5 mg of each ZFN-encoding plasmid and 15 mg of pEGFP-N1 (Clontech) together with 30 mg of ssODNs (5 0 -GACTTATGTCTTGAATTTGTTTTTGTAGGCTCCAAAACCAAGAAGGGAG TGGTGCATGGTGTGGCAACAGGTAAGCTCCATTGTGCTTATATCCAAAGAT GATATTTAAAGTAT-3 0 ; Integrated DNA Technologies, Iowa). Cells were maintained on MEF feeder layers for 72 hr in the presence of ROCK Inhibitor followed by FACS sorting (FACS-Aria; BD-Biosciences) of a single-cell suspension for eGFP-expressing cells and were subsequently plated at a low density in hESC medium supplemented with ROCK inhibitor for the first 24 hr. Individual colonies were picked and expanded 10-14 days after electroporation.
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Expression Microarray data and SNP 6.0 CNV array data have been submitted to the Gene Expression Omnibus (GEO) and are available under accession number GSE29774. ) for correction of A53T (G209A) mutation (wild-type Donor). Genomic DNA was digested using an A53T (G209A) allele-specific Tsp45I restriction digest (A53T mutation creates additional Tsp45I restriction site). 
